{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:23:11Z","timestamp":1790374991348,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.intimp.2022.108555","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T04:15:41Z","timestamp":1643688941000},"page":"108555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["The interactions of paclitaxel with tumour microenvironment"],"prefix":"10.1016","volume":"105","author":[{"given":"Ding-Li","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108555_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0015","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.108555_b0020","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2022.108555_b0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0030","doi-asserted-by":"crossref","first-page":"103180","DOI":"10.1016\/j.critrevonc.2020.103180","article-title":"Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives","volume":"157","author":"Mortezaee","year":"2021","journal-title":"Critical Rev. Oncol.\/Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108555_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","article-title":"Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review","volume":"57","author":"Stage","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2022.108555_b0040","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccr.2007.04.011","article-title":"Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs","volume":"11","author":"Swanton","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2022.108555_b0045","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-induced cell death: where the cell cycle and apoptosis come together","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"key":"10.1016\/j.intimp.2022.108555_b0050","doi-asserted-by":"crossref","first-page":"1901858","DOI":"10.1002\/adhm.201901858","article-title":"Co-delivery of paclitaxel and interleukin-12 regulating tumor microenvironment for cancer immunochemotherapy","volume":"9","author":"Hu","year":"2020","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.intimp.2022.108555_b0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2020","journal-title":"Medicina"},{"key":"10.1016\/j.intimp.2022.108555_b0060","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2022.108555_b0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/acs.molpharmaceut.7b00808","article-title":"Facile deposition of manganese dioxide to albumin-bound paclitaxel nanoparticles for modulation of hypoxic tumor microenvironment to improve chemoradiation therapy","volume":"15","author":"Meng","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.intimp.2022.108555_b0070","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3389\/fimmu.2019.01530","article-title":"Multiple interactions between cancer cells and the tumor microenvironment modulate TRAIL signaling: implications for TRAIL receptor targeted therapy","volume":"10","author":"de Looff","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108555_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10147-021-02074-9","article-title":"Key promoters of tumor hallmarks","volume":"27","author":"Mortezaee","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/170381","article-title":"Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment","volume":"2014","author":"Mukaida","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2022.108555_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/170381","article-title":"Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment","volume":"2014","author":"Mukaida","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.intimp.2022.108555_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0095","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12185-011-0799-6","article-title":"The mechanisms of cancer immunoescape and development of overcoming strategies","volume":"93","author":"Yaguchi","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.intimp.2022.108555_b0105","doi-asserted-by":"crossref","first-page":"106807","DOI":"10.1016\/j.intimp.2020.106807","article-title":"The interactions and communications in tumor resistance to radiotherapy: therapy perspectives","volume":"87","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1-2","key":"10.1016\/j.intimp.2022.108555_b0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/CritRevOncog.2014011142","article-title":"NK cells in the tumor microenvironment","volume":"19","author":"Larsen","year":"2014","journal-title":"Critical Reviews\u2122 Oncog."},{"key":"10.1016\/j.intimp.2022.108555_b0115","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2022.108555_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mc.23354","article-title":"Amateur antigen-presenting cells in the tumor microenvironment","volume":"61","author":"Darragh","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.intimp.2022.108555_b0130","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108555_b0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2022.108555_b0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/JLB.4RU0819-150RR","article-title":"Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in Prostate cancer","volume":"107","author":"Sanaei","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"16","key":"10.1016\/j.intimp.2022.108555_b0155","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.3390\/ijms22168470","article-title":"Tumor-Associated Macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.108555_b0160","first-page":"91","article-title":"Chemo-immunotherapy: role of indoleamine 2, 3-dioxygenase in defining immunogenic versus tolerogenic cell death in the tumor microenvironment","author":"Johnson","year":"2017","journal-title":"Tumor Immune Microenviron. Cancer Prog. Cancer Ther."},{"key":"10.1016\/j.intimp.2022.108555_b0165","first-page":"1","article-title":"Targeting of the tumor immune microenvironment by metformin","author":"Wu","year":"2021","journal-title":"J. Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.intimp.2022.108555_b0170","doi-asserted-by":"crossref","first-page":"152729","DOI":"10.1016\/j.prp.2019.152729","article-title":"Tumor microenvironment components: Allies of cancer progression","volume":"216","author":"Ribeiro Franco","year":"2020","journal-title":"Pathol. \u2013 Res. Pract."},{"key":"10.1016\/j.intimp.2022.108555_b0175","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.2017.74.9812","article-title":"Pathologic angiogenesis of malignant vascular sarcomas: implications for treatment","volume":"36","author":"Khan","year":"2018","journal-title":"J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0180","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.108555_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay1357","article-title":"Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy","volume":"5","author":"Williford","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2022.108555_b0190","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-12-4366","article-title":"IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment","volume":"73","author":"Wong","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0195","doi-asserted-by":"crossref","first-page":"119627","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.108555_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2022.108555_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"issue":"2016","key":"10.1016\/j.intimp.2022.108555_b0210","first-page":"962","article-title":"Tolerogenic phenotype of IFN-\u03b3-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine\/AhR-IDO loop","volume":"197","author":"Li","year":"1950","journal-title":"J. Immunozl. (Baltimore Md.: 1950)"},{"key":"10.1016\/j.intimp.2022.108555_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01360","article-title":"Indoleamine 2,3-dioxygenase and tolerance: where are we now?","volume":"8","author":"Mellor","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0220","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cellimm.2010.03.001","article-title":"Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice","volume":"263","author":"Pfannenstiel","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0225","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1202781","article-title":"Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model","volume":"190","author":"Sevko","year":"2013","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0230","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/1547691X.2011.642418","article-title":"Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner","volume":"9","author":"Michels","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.intimp.2022.108555_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ T cells in tumor microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.intimp.2022.108555_b0240","doi-asserted-by":"crossref","first-page":"108707","DOI":"10.1016\/j.clim.2021.108707","article-title":"The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives","volume":"226","author":"Majidpoor","year":"2021","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.intimp.2022.108555_b0245","first-page":"1","article-title":"Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0250","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ijrobp.2020.07.2299","article-title":"Characterization of intrinsic radiosensitivity and immune cell infiltrates in bladder cancer","volume":"108","author":"Grass","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0255","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.ijrobp.2021.07.845","article-title":"Radiosensitivity and immune cell infiltration signature predict clinical outcome of patients in the molecular taxonomy of breast cancer international consortium (METABRIC) study cohort","volume":"111","author":"Kang","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.intimp.2022.108555_b0260","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/cancers12102991","article-title":"KIR+ CD8+ T lymphocytes in cancer immunosurveillance and patient survival: gene expression profiling","volume":"12","author":"Gimeno","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2022.108555_b0265","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00432-019-03036-5","article-title":"Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer","volume":"145","author":"Vihervuori","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0270","doi-asserted-by":"crossref","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","article-title":"Abscopal effect in radioimmunotherapy","volume":"85","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0275","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0280","article-title":"Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4-independent and dependent pathways","author":"Lau","year":"2019","journal-title":"AACR"},{"key":"10.1016\/j.intimp.2022.108555_b0285","doi-asserted-by":"crossref","first-page":"106761","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0290","doi-asserted-by":"crossref","first-page":"365101","DOI":"10.1088\/1361-6528\/ab94dc","article-title":"Paclitaxel\/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer","volume":"31","author":"Qin","year":"2020","journal-title":"Nanotechnology"},{"issue":"4","key":"10.1016\/j.intimp.2022.108555_b0295","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2022.108555_b0300","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1158\/1078-0432.CCR-18-2243","article-title":"Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non\u2013small cell lung cancer patients","volume":"25","author":"de Goeje","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0305","first-page":"3813","article-title":"Regulatory T-cell density and cytotoxic T lymphocyte density are associated with complete response to neoadjuvant paclitaxel and carboplatin chemoradiotherapy in gastric cancer","volume":"16","author":"Huang","year":"2018","journal-title":"Exp. Therap. Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.108555_b0310","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00262-019-02412-x","article-title":"Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer","volume":"68","author":"Heeren","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"15","key":"10.1016\/j.intimp.2022.108555_b0315","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1158\/0008-5472.CAN-04-3792","article-title":"Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer","volume":"65","author":"Coleman","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108555_b0325","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00262-004-0617-6","article-title":"Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production","volume":"54","author":"Kubo","year":"2005","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.intimp.2022.108555_b0330","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1272\/jnms.81.211","article-title":"Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer","volume":"81","author":"Miura","year":"2014","journal-title":"J. Nippon Med. School = Nippon Ika Daigaku zasshi"},{"key":"10.1016\/j.intimp.2022.108555_b0335","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12967-015-0567-0","article-title":"Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy","volume":"13","author":"Muraro","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2022.108555_b0340","article-title":"The inhibitory effect of cisplatin, paclitaxel, and pemetrexed on the growth of PC9GR cells resistant to NK cell-mediated cytotoxicity during the COVID-19 pandemic","volume":"39","author":"Mohiuddin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0345","first-page":"735","article-title":"Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression","volume":"25","author":"Loubani","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0350","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0355","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00262-008-0586-2","article-title":"Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse","volume":"58","author":"Vicari","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2022.108555_b0360","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2009.01.027","article-title":"Regulatory T cells and Toll-like receptors: what is the missing link?","volume":"9","author":"Dai","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0365","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1210910","article-title":"TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours","volume":"27","author":"Conroy","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2022.108555_b0370","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clim.2008.07.013","article-title":"Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy","volume":"129","author":"Zhang","year":"2008","journal-title":"Clin. Immunol. (Orlando Fla.)"},{"key":"10.1016\/j.intimp.2022.108555_b0375","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0380","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.108555_b0385","doi-asserted-by":"crossref","first-page":"e1596004","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2022.108555_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2021.07.009","article-title":"LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages","volume":"138","author":"Xing","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.07.002","article-title":"Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer","volume":"461","author":"Parayath","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2022.108555_b0400","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.3892\/or.2017.5586","article-title":"Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer","volume":"37","author":"Yamaguchi","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2022.108555_b0405","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0410","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","article-title":"Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer","volume":"5","author":"Cullis","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2022.108555_b0415","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2014.00062","article-title":"Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment","volume":"4","author":"Augsten","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0420","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3892\/ijo.2013.1801","article-title":"Low-dose paclitaxel modulates tumour fibrosis in gastric cancer","volume":"42","author":"Tsukada","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0425","doi-asserted-by":"crossref","first-page":"119337","DOI":"10.1016\/j.ijpharm.2020.119337","article-title":"Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel","volume":"584","author":"Fourniols","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2022.108555_b0430","first-page":"337","article-title":"Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma","volume":"38","author":"Miyashita","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104745","article-title":"TGF-\u03b2 in radiotherapy: Mechanisms of tumor resistance and normal tissues injury","volume":"155","author":"Farhood","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2022.108555_b0440","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1172\/JCI95200","article-title":"Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance","volume":"128","author":"Leung","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.intimp.2022.108555_b0445","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/biomedicines9060597","article-title":"Simultaneous targeting tumor cells and cancer-associated fibroblasts with a paclitaxel-hyaluronan bioconjugate: in vitro evaluation in non-melanoma skin cancer","volume":"9","author":"Bellei","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2022.108555_b0450","first-page":"2081","article-title":"CAFs enhance paclitaxel resistance by inducing EMT through the IL-6\/JAK2\/STAT3 pathway","volume":"39","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2022.108555_b0455","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/abbs\/gmab032","article-title":"CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K\/AKT\/mTOR pathway","volume":"53","author":"Chen","year":"2021","journal-title":"Acta Biochim. Biophy. Sin."},{"key":"10.1016\/j.intimp.2022.108555_b0460","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ijc.31744","article-title":"Myeloid-derived suppressor cells: roles in the tumor microenvironment and tumor radiotherapy","volume":"144","author":"Yin","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0465","doi-asserted-by":"crossref","first-page":"107895","DOI":"10.1016\/j.intimp.2021.107895","article-title":"Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells","volume":"98","author":"Mu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0470","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.intimp.2014.06.012","article-title":"Baccatin III, a precursor for the semisynthesis of paclitaxel, inhibits the accumulation and suppressive activity of myeloid-derived suppressor cells in tumor-bearing mice","volume":"21","author":"Lee","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108555_b0475","doi-asserted-by":"crossref","first-page":"104274","DOI":"10.1016\/j.cellimm.2020.104274","article-title":"Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: a pilot study","volume":"360","author":"Gebhardt","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2022.108555_b0480","doi-asserted-by":"crossref","first-page":"120057","DOI":"10.1016\/j.lfs.2021.120057","article-title":"The impact of hypoxia on immune state in cancer","volume":"286","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.108555_b0485","first-page":"519","article-title":"Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment","volume":"12","author":"Chen","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2022.108555_b0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000119756","article-title":"Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production","volume":"81","author":"Kim","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.intimp.2022.108555_b0495","first-page":"2330","article-title":"Paclitaxel-induced hypothermia and hypoperfusion increase breast cancer metastasis and angiogenesis in mice","volume":"15","author":"Ami","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2022.108555_b0500","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1533034616665720","article-title":"Knockdown of hypoxia-inducible factor 1\u03b1 improved the efficacy of low-dose metronomic chemotherapy of paclitaxel in human colon cancer xenografts","volume":"16","author":"Zhang","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2022.108555_b0505","doi-asserted-by":"crossref","first-page":"865732","DOI":"10.1155\/2014\/865732","article-title":"Tumor angiogenesis therapy using targeted delivery of paclitaxel to the vasculature of breast cancer metastases","volume":"2014","author":"Zhu","year":"2014","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.intimp.2022.108555_b0510","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3349\/ymj.2013.54.2.374","article-title":"Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells","volume":"54","author":"Hwang","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.intimp.2022.108555_b0515","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ijc.33559","article-title":"Outcomes on anti-VEGFR-2\/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma","volume":"149","author":"Kankeu Fonkoua","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2022.108555_b0520","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","article-title":"DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy","volume":"165","author":"Tiptiri-Kourpeti","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2022.108555_b0530","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0535","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/1547691X.2012.655343","article-title":"Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice","volume":"9","author":"Sevko","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.intimp.2022.108555_b0540","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s40425-019-0593-1","article-title":"Carboplatin\/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors","volume":"7","author":"Domingos-Pereira","year":"2019","journal-title":"J. ImmunoTher. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2022.108555_b0545","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00262-012-1345-y","article-title":"Concomitant combination of active immunotherapy and carboplatin-or paclitaxel-based chemotherapy improves anti-tumor response","volume":"62","author":"Diaz","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2022.108555_b0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr787","article-title":"Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2\/neu in a murine mammary carcinoma model","volume":"6","author":"Eralp","year":"2004","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0555","first-page":"3689","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108555_b0560","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors - clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell. Oncol. (Dordrecht)"},{"key":"10.1016\/j.intimp.2022.108555_b0565","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/OTT.S122974","article-title":"nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors","volume":"10","author":"Soliman","year":"2017","journal-title":"OncoTargets Therapy"},{"key":"10.1016\/j.intimp.2022.108555_b0570","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.7150\/thno.45391","article-title":"Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2022.108555_b0575","doi-asserted-by":"crossref","first-page":"1906605","DOI":"10.1002\/adfm.201906605","article-title":"Enhancing triple negative breast cancer immunotherapy by ICG-templated self-assembly of paclitaxel nanoparticles","volume":"30","author":"Feng","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.intimp.2022.108555_b0580","article-title":"Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma","author":"Li","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0585","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.298","article-title":"Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC)","volume":"37","author":"Wainberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0590","article-title":"Clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma","volume":"57","author":"Suzuki","year":"2021","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"10.1016\/j.intimp.2022.108555_b0595","doi-asserted-by":"crossref","unstructured":"G. Oner, S. Onder, H. Karatay, N. Ak, M. Tukenmez, M. Muslumanoglu, A. Igci, A. Dinccag, V. Ozmen, A. Aydiner, Clinical Impact of PD-L1 Expression in Triple Negative Breast Cancer Patients With Residual Tumor Burden After Neoadjuvant Chemotherapy, 2021.","DOI":"10.21203\/rs.3.rs-338452\/v1"},{"key":"10.1016\/j.intimp.2022.108555_b0600","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2022.108555_b0605","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108555_b0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-98113-6","article-title":"Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer","volume":"11","author":"Ghebeh","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108555_b0615","doi-asserted-by":"crossref","DOI":"10.2217\/lmt-2019-0018","article-title":"Chemotherapy and\/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?","volume":"9","author":"Gravara","year":"2020","journal-title":"Lung Cancer Manag."},{"key":"10.1016\/j.intimp.2022.108555_b0620","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy","volume":"12","author":"Zhang","year":"2020","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"10.1016\/j.intimp.2022.108555_b0625","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108555_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.666691","article-title":"Consolidation with pembrolizumab and nab-paclitaxel after induction platinum-based chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Patel","year":"2021","journal-title":"Front. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:17:22Z","timestamp":1730837842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692200039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":126,"alternative-id":["S156757692200039X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108555","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interactions of paclitaxel with tumour microenvironment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108555"}}